Company / R&D Expense
Annexon, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$119.4M
FY2024
5-year range
$49.3M / $119.4M
FY2020-FY2024
Trend
+5.0%
vs FY2023
Sector context
#124 of 209
Health Care
What the data says
At $119M, Annexon, Inc.'s r&d expense ranks #124 of 209 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $25M in FY2019 to $119M in FY2024.
Based on SEC 10-K filings.
$119M in FY2024 with a 5-year CAGR of +37.3%.
Improved from $113M to $119M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.1%
- 5-Year CAGR
- +37.3%
- 10-Year CAGR
- -
Sector benchmark
#124 of 209 in Health CareTop 59% of 209This company $119.4M Sector average $647.6M
▼
-81.6% below sector average
Key checks
Key Insights
- Annexon, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +37.3%, indicating consistent growth.
- In FY2024, r&d expense increased 5.0% year-over-year.
- Ranks #124 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $119.4M | +5.0% |
| FY2023 | $113.8M | +1.1% |
| FY2022 | $112.5M | +12.4% |
| FY2021 | $100.1M | +103.1% |
| FY2020 | $49.3M | +100.9% |
| FY2019 | $24.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026